iRadimed Corporation $IRMD Shares Newly Acquired by Bank of America Corp DE

Key Points

• Institutional ownership increased: Bank of America acquired 19,189 iRadimed shares worth approximately $1.8 million, while BlackRock and other firms also established or expanded positions. Institutions now own 92.34% of the company.
• Analyst sentiment is moderately bullish: iRadimed has an average “Moderate Buy” rating and a consensus price target of $120, despite recent hold ratings from some analysts.
• Quarterly results beat expectations: The company reported $0.46 in adjusted earnings per share and $20.47 million in revenue, exceeding estimates, while maintaining FY 2026 EPS guidance of $2.09 to $2.24. It also declared a quarterly dividend of $0.20 per share.

Bank of America Corp DE purchased a new position in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 19,189 shares of the medical equipment provider's stock, valued at approximately $1,834,000. Bank of America Corp DE owned 0.15% of iRadimed as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also added to or reduced their stakes in IRMD. BlackRock Inc. acquired a new position in shares of iRadimed during the second quarter worth approximately $92,485,000. Dimensional Fund Advisors LP increased its stake in iRadimed by 4.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider's stock valued at $21,768,000 after purchasing an additional 9,017 shares in the last quarter. Ranger Investment Management L.P. bought a new stake in iRadimed during the 2nd quarter valued at $9,398,000. Bank of New York Mellon Corp acquired a new position in iRadimed during the second quarter worth $7,252,000. Finally, Sei Investments Co. raised its holdings in iRadimed by 17.2% during the first quarter. Sei Investments Co. now owns 74,304 shares of the medical equipment provider's stock worth $7,153,000 after buying an additional 10,908 shares during the last quarter. Institutional investors own 92.34% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on IRMD shares. Wall Street Zen cut shares of iRadimed from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings upgraded shares of iRadimed from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, September 9th. Finally, Needham & Company LLC began coverage on shares of iRadimed in a report on Tuesday, September 22nd. They issued a "hold" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $120.00.

Insider Buying and Selling

In other iRadimed news, Director Monty K. Allen sold 1,419 shares of the business's stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total value of $122,615.79. Following the transaction, the director owned 19,581 shares of the company's stock, valued at approximately $1,691,994.21. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 34.60% of the company's stock.

iRadimed Price Performance

NASDAQ IRMD opened at $86.22 on Thursday. The company has a fifty day moving average price of $87.52 and a 200-day moving average price of $91.42. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of 48.17 and a beta of 0.89. iRadimed Corporation has a 1 year low of $68.68 and a 1 year high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The company had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, research analysts anticipate that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, August 14th. iRadimed's dividend payout ratio (DPR) is 44.69%.

About iRadimed

iRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on equipment that enables clinicians to provide continuous care and monitor patients safely while they are undergoing MRI procedures, where conventional medical devices may pose safety or compatibility challenges.

Its product portfolio includes the MRidium MRI-compatible infusion pump systems, which are designed to deliver intravenous medications and fluids during MRI examinations, as well as MRI-compatible patient monitoring systems and related accessories.

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.